Log in or Sign up for Free to view tailored content for your specialty!
Retina/Vitreous News
FDA clears fully autonomous AI for portable diabetic retinopathy screening
AEYE Health has received the first-ever FDA clearance for a fully autonomous AI that can diagnose referable diabetic retinopathy using retinal images taken by a handheld camera, according to a company-issued press release.
Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy
Researchers reported an association between the severity of internal carotid artery stenosis and retinal health in proliferative diabetic retinopathy, highlighting the importance of carotid artery evaluations in these patients.
Log in or Sign up for Free to view tailored content for your specialty!
Ocugen doses second cohort in trial of OCU410 for geographic atrophy
Ocugen has announced that dosing is complete in the second cohort of its phase 1/2 ArMaDa clinical trial to assess the safety of OCU410, a modifier gene therapy candidate for geographic atrophy.
RevOpsis raises $16.5 million to advance neovascular AMD treatment candidate
RevOpsis Therapeutics closed its first seed funding round and raised $16.5 million to advance RO-104, its lead candidate for the treatment of neovascular age-related macular degeneration.
Eyecelerator@ASCRS: Healio’s top meeting videos
Catch up on the most popular videos from Eyecelerator@ASCRS as Healio’s coverage of the American Society of Cataract and Refractive Surgery meeting continues.
AI-assisted technology makes retinal imaging 100 times faster, with greater contrast
Researchers at NIH have developed an AI-assisted strategy that can improve cellular contrast of retinal images captured via OCT while reducing image acquisition and processing time by nearly 100-fold.
Oral minocycline fails to slow rate of geographic atrophy enlargement in AMD
Oral minocycline was not associated with a reduction in geographic atrophy enlargement over 24 months vs. a 9-month run-in period among patients with age-related macular degeneration, according to a study in JAMA Ophthalmology.
VIDEO: Neurotech prepares to submit license application for NT-501
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on encapsulated cell therapy for the extended treatment of retinal diseases.
ABBV-RGX-314 well tolerated with sustained anti-VEGF protein expression in wet AMD
Subretinal delivery of ABBV-RGX-314 gene therapy demonstrated safety and sustained anti-VEGF protein expression at higher doses in patients with neovascular age-related macular degeneration, according to a study.
Progress has been slow in stem cell therapy for retinal diseases
BOSTON — Stem cell therapies for retinal diseases come with advantages and disadvantages, according to a speaker at the American Society of Cataract and Refractive Surgery meeting.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read